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ABSTRACT 
Background: 
Epstein Barr Virus (EBV) infection is closely associated with multiple sclerosis (MS), 
but the relationship between viral load and disease activity is unclear. This study 
tested the observed levels of salivary EBV in MS, as a first step in investigating this 
relationship. 
Methods: 
Real-time quantitative PCR (qPCR) was used to measure EBV DNA levels in saliva 
samples from three separate Multiple Sclerosis (MS) patient cohorts. 
Results: 
The qPCR assay was used to delineate EBV shedding, defined here as a reliably 
detectable level of extracellular EBV DNA in saliva. Frequency of EBV shedding was 
found to be similar across the groups, with 20-25% of subjects releasing virus on any 
given sampling date. Diurnal variation in EBV count was tested in one of the cohorts, 
in which 26% of subjects showed more than a 10-fold difference between the highest 
and lowest EBV levels on a single day. In the same cohort, elevated viral levels at 
one time point did not predict elevated viral levels at a subsequent time point. 
Conclusions: 
These results indicate that EBV lytic activity in a subject cannot be inferred from a 
single measure of EBV in saliva. Also, subjects do not appear to be behave 
constantly as “EBV shedders” or “nonshedders”. The assay is useful in giving a clear 
indication of salivary gland EBV lytic activity across a patient cohort – for example, in 
testing anti-viral drugs in MS. 
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BACKGROUND 
Epstein Barr Virus (EBV) infection is the virus most strongly associated with multiple 
sclerosis (MS) (Christensen, 2006; Pender & Burrows, 2014), with almost all MS 
patients (MSers) found to be seropositive for EBV (Bray, Bloomer, Salmon, Bagley, 
& Larsen, 1983; Wandinger et al., 2000).  
Evidence for a pathogenic role of EBV in MS is supported by elevated EBV antibody 
titres in MS patient cohorts (Farrell et al., 2009; Latham et al., 2016). In one such 
study (Wandinger et al 2000), antibody response to EBV (IgG) early antigen (EA) 
was found in 73% of patients with disease exacerbations and in none of those with 
clinically stable disease. Early antigen response is a marker of acute viral infection, 
at which time extensive release of viral particles into saliva (viral shedding) occurs 
(Hadinoto, Shapiro, Sun, & Thorley-Lawson, 2009). Such particles consist of a lipid 
envelope containing virally-encoded glycoproteins, a protein capsid and viral DNA 
(Perera, Samaranayake, & Tsang, 2010). Arguably, increased antibody titres could 
arguably reflect immune dysregulation (Hunter & Hafler, 2000) and may not be linked 
temporally to viral reactivation. For this reason, measurement of EBV levels using 
qPCR may be preferable to antigen response assays as a measure of virus 
reactivation. One such study showed elevated salivary EBV levels in children with 
MS (Yea et al., 2013), and a recent investigation found detectable salivary EBV to be 
20x more frequent in adults with relapsing MS compared with healthy controls, 
although this increase in shedding frequency was not found to be statistically 
significant (Giess et al., 2017). The temporal association between EBV release and 
MS disease activity measured by magnetic resonance imaging (MRI) is unclear. A 
recent investigation demonstrated a negative correlation between MRI activity and 
EBV titres 4-6 weeks before the MRI scan (Latham et al., 2016).  
The purpose of the present study was to establish a reliable protocol for defining and 
quantifying salivary EBV, and then identify the normal patterns of salivary EBV levels 
in MS. Knowledge of expected levels of salivary EBV in MS would ensure that future 
studies have sufficient statistical power to identify the relationship, if any, between 
viral load and disease activity. A clear association between EBV shedding and 
disease activity would also justify a trial of antiviral agents targeting EBV in MS. 
 
METHODS 
1. Data sets were derived from three cohorts as defined below: 
INSPIRE (Isentress Pilot Study in Relapsing MS). This comprised 20 patients with 
active relapsing MS. Samples were taken at monthly intervals over 7 months 
ExIMS (Exercise Intervention for MS trial). This consisted of 120 patients with 
relapsing MS. Sampling was undertaken three times over one year. Four separate 
samples were taken at 3-hourly intervals on each sampling date. 
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MEAVIS (Measurement of EBV in Saliva). This consisted of 18 MSers who self-
collected weekly samples over 3 months 
Use of samples in all three cohorts approved by Ethics committees. 
2. Analysis of Samples 
All samples were analysed in the same laboratory at the Blizard Institute, Queen 
Mary University of London. 
Approximately 1-2ml of saliva was collected at each sampling interval. DNA was 
isolated from these samples using standard protocols QiaSymphony (robot) SP 
Virus/Bacteria Mini-kit (Qiagen, Hilden, Germany) for the INSPIRE samples and 
Ambion PureLink 96 kit (Thermo Fisher Scientific, Waltham, Mass, USA) for the 
ExIMS and MEAVIS samples. No adjustment was made to DNA concentration. 
The QPCR method was validated as part of the INSPIRE clinical trial, and an 
identical method applied to all three cohorts. EBV DNA was detected by a Taqman 
assay targeted to a non-repeated sequence of the EBV polymerase gene (Gallagher 
et al., 1999) and a pyruvate dehydrogenase (PDH) sequence (Bissett et al., 2011) 
was included as a reference gene in a multiplex PCR. The assay used a Qiagen 
QuantiTect Multiplex PCR Kit with a standard protocol (95°C 15 mins; (95°C 60 s, 
60°C 60s) x 40 cycles, reaction volumes of 25μl, primer and probe concentrations 
0.4μM and 0.1μM respectively). Patient samples were run in duplicate, and a 
standard curve was included on each PCR plate using a dilution series derived from 
quantitated EBV DNA (Agilent). The CT (cycle threshold) value was set at the 
midpoint of the exponential phase of the PCR and normalised across PCR runs to 
give uniformity across all PCR runs. The assay returned an absolute copy number of 
EBV per sample (copies per μl of saliva), calculated directly from the standard curve. 
The PDH amplification was used to confirm the presence of genomic DNA but was 
not used to calculate the EBV copy number. A negative amplification of both EBV 
and PDH may indicate a failed PCR or a failed DNA extraction. Analysis of samples 
was repeated once if both EBV and PDH failed to amplify. Analysis was also 
repeated if one of the two EBV replicates failed to amplify, and samples were 
classed as missing data if this repetition was unsuccessful. 
 
RESULTS 
1. Reliability of Assay 
An important goal of the study was to establish a reliable definition of EBV shedding. 
In earlier studies, the presence of EBV in saliva (at levels of as low as 1 copy per �l) 
has been taken to indicate viral shedding: this assumption was found to be unreliable 
in our study. Although low copy numbers were detectable with this assay, the 
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analysis was only found to be fully reproducible (with coefficient of variation <1.4) for 
EBV levels above 3 copies/µl (equivalent CT value >36). 
As cellular remnants are present in saliva, very low titres of EBV DNA sample could 
be due to the presence of cellular DNA in the samples. For this reason, the presence 
of cellular (genomic) DNA was measured in the ExIMS cohort using the PDH 
primer/probe set. No correlation was found between PDH and EBV titres in this 
cohort (Spearman Rank Correlation, Rs= 0.0457, p=0.33), which suggests that EBV 
detected in these assays was mainly extracellular and due to active viral shedding. 
For the purpose of this assay, shedding was defined as a salivary EBV concentration 
greater than 5.8 copies/µl: this is equivalent to one standard deviation above the 
median in the ExIMS dataset. This level is above the minimum reliable detection limit 
for this assay, and also minimises the effects of cellular remnants in saliva. 
2. EBV Shedding in MS: comparison of 3 MS cohorts 
Table 1 compares salivary EBV in our 3 populations to help predict the expected 
level of shedding in a typical MS population. 
Population Patients Samples EBV present Shedding 
(>5.8 copies/µl) 
% of subjects with EBV detected* 
 
 N N N % N % EBV detected % Shedding % 
INSPIRE 20 87 36 41.4 21 24.1 70.0 45.0 
ExIMS 119 280** 107 35.2 64 22.9 68.6 37.3 
MEAVIS 18 114 43 37.7 24 21.1 61.1 44.4 
 
Table 1. Number of samples collected per cohort: (sample number, shedding, etc.)  
(* subjects with any positive EBV samples during the study) 
(** number of sampling dates, in which 4 samples were taken within a 24h period)  
The results show that 20-25% of subjects were found to be releasing salivary EBV at 
>5.8 copies/µl (shedding EBV) on a given date. 
3. Temporal patterns of salivary EBV levels in the EXIMs population. 
In the ExIMS study, sampling occurred in all months of the year, so it was possible to 
test seasonal variation in EBV counts. Cold months were assigned lower scores 
(January = 1, December & February = 2, November & March = 3) and warmer 
months assigned higher scores (October & April = 4, September & May = 5, August 
& June = 6, July = 7). No correlation found between these scores and salivary EBV 
levels taken in these months (r2 = 0.0038), strongly indicating no seasonal effect. 
In the ExIMS population, sampling at four time points on a single day allowed diurnal 
variation to be measured. Although morning EBV counts were on average >60% 
higher than afternoon values, in 10% of samples there was more than a 30-fold 
difference between maximum and minimum EBV counts on a single day. Similarly, 
5 
 
26% of samples showed more than a 10-fold difference between maximum and 
minimum EBV counts. 
4. Are some subjects either “shedders” or “non-shedders”? 
This analysis investigated whether the distribution of viral load scores was non-
random with respect to subject. As consecutive high scores 1 month apart could 
relate to a single shedding episode, this was exclusively tested in the ExIMS 
population in which sample dates were at least 3 months apart. 
The null hypothesis was that there was no difference in subsequent shedding 
behaviour between subjects found to be shedding or not at baseline: 
21 subjects were found to be shedding at baseline, of whom 8 were shedding 3 
months later. 
73 were not shedding at baseline, of which 16 were found to shedding 3 months 
later. 
No significant difference was observed between these groups (Fisher’s exact test, 
p=0.16), supporting the null hypothesis: repeat sampling showed that people with 
MS could not be divided into discrete groups of “shedders” and “non-shedders”. 
 
DISCUSSION 
a. Methodology: 
Previous studies have equated detectable EBV with shedding, but this study found 
the detection of low levels of salivary EBV to be unreliable. Additionally, as saliva 
typically contains a cellular fraction, any sample from an EBV positive subject will 
potentially contain trace levels of intracellular EBV. This study applied a threshold 
level for EBV shedding for the detection of extracellular EBV across separate 
cohorts. 
b. EBV shedding across separate MS groups: 
The percentage of samples (subjects/date) with EBV levels above the defined 
shedding threshold was found to be very similar across the three cohorts (20-25%). 
This figure provides an expected frequency of EBV shedding in MS samples, which 
should be useful in future studies. 
 Across the three cohorts, between 37% and 45% of subjects were found to be 
shedding EBV at some point, which is similar to the result of a previous study in 
which 41% of subjects were found to be shedding (Hollsberg et al., 2005). An 
important caveat is that the percentage of subjects found to be shedding will 
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increase with increased sampling frequency and study duration; therefore this figure 
should not be used in predicting the necessary sample size in future studies. 
c. Variation in EBV counts in individuals: 
The present study found that salivary EBV levels in a single subject can vary 
markedly over short periods; 10% of patient sample sets showed a greater than 30-
fold difference between the highest and lowest EBV counts on a given day. In one 
previous study, similar variation in copy number was observed across samples taken 
at 3-hourly intervals, although the extent of variation was obscured by reporting EBV 
levels as log copies per ml – leading to the erroneous (and cited) conclusion that 
virus shedding is relatively stable over short periods (Hadinoto et al., 2009; Huynh & 
Rong, 2012). 
Data from the ExIMS study showed that for any given subject, EBV copy number at 
one time-point did not predict the EBV level at a subsequent time point. This echoes 
the results of a previous study that found the distinction between “high shedders” 
and “low shedders” was a function of variation within individuals over time, rather 
than variation between individuals (Hadinoto et al., 2009). 
d. Implications for future studies 
To date, it has proved difficult to establish a relationship between MS and EBV, 
given that around 95% of most healthy populations are positive compared to about 
99% of MSers (Ascherio & Munger, 2007). The example of clinical poliomyelitis 
shows that a similarly ubiquitous infectious agent can be largely asymptomatic and 
yet cause a serious condition in some. Therefore, if EBV is found to have a 
pathogenic role in MS, it may be possible to prevent it by eliminating EBV infection 
completely or by blocking the pathway that leads from EBV infection to disease 
development. 
Although relapses were reported by some of our subjects, the comparison of disease 
activity and EBV copy number was not a primary goal in any of the three studies 
described here. The logical follow-up to this study is to test whether EBV shedding is 
related to disease activity across an entire cohort, for example, by comparing 
salivary EBV levels with MRI activity. If salivary EBV levels are found to be linked to 
MS disease activity, it would then be important to test whether EBV antiviral drugs 
can be used to treat or even prevent the disease. 
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